NasdaqCM - Nasdaq Real Time Price USD

Anixa Biosciences, Inc. (ANIX)

Compare

2.6900

+0.3100

+(13.03%)

At close: April 9 at 4:00:02 PM EDT

2.6500

-0.04

(-1.49%)

After hours: April 9 at 4:52:17 PM EDT

Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Covering Breast Cancer Vaccine Technology

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a new patent related to the Company's innovative breast cancer vaccine technology. The patent along with others related to this technology, has been exclusively licensed to Anixa Biosciences, by Cleveland Clinic. The patent will expand the scope

PR Newswire 16 hours ago

ANIX
+13.03%
EXCLUSIVE: Anixa Biosciences Receives Key US Patent Nod For Breast Cancer Vaccine Patent

On Wednesday, the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for a new patent related to Anixa Biosciences, Inc.'s (NASDAQ:ANIX) breast cancer vaccine technology. Cleveland Clinic has exclusively licensed the patent and others related to this technology to Anixa Biosciences. The patent will expand the scope of immunogenic compositions utilized in Anixa's breast cancer vaccine. Also Read: EXCLUSIVE: Anixa Biosciences Inks Letter of Intent with Austria-Based VER

Benzinga 16 hours ago

ANIX
+13.03%
Anixa Biosciences to Present at the Jones Las Vegas Healthcare and Technology Innovation Conference on April 9th

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced its participation in the Jones Las Vegas Healthcare and Technology Innovation Conference, to be held on April 8-9, 2025, at The Venetian Resort in Las Vegas, Nevada.

PR Newswire 8 days ago

ANIX
+13.03%
Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has entered into a letter of intent with VERDI Solutions, GmbH to develop personalized and off-the-shelf peptide vaccines for cancer patients.

PR Newswire 15 days ago

ANIX
+13.03%
EXCLUSIVE: Anixa Biosciences Inks Letter of Intent with Austria-Based VERDI Solutions To Develop AI-Guided Personalized Cancer Vaccines

On Tuesday, Anixa Biosciences, Inc. (NASDAQ:ANIX) entered into a letter of intent with VERDI Solutions GmbH to develop personalized and off-the-shelf peptide vaccines for cancer patients. VERDI Solutions, headquartered in Vienna, Austria, is developing personalized cancer treatment by integrating artificial intelligence (AI) and advanced cloud computing to accelerate the development and implementation of personalized cancer vaccines. VERDI's cloud-computing platform enables the rapid development

Benzinga 15 days ago

ANIX
+13.03%
Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a key patent application covering its ovarian cancer vaccine technology. The patent includes broad claims related to methods of eliciting an immune response targeting Anti-Mullerian Hormone Receptor, Type II (AMHR2), a promising target for ovaria

PR Newswire 16 days ago

ANIX
+13.03%
EXCLUSIVE: Anixa Biosciences Poised To Receive US Patent For Ovarian Cancer Vaccine

On Monday, the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for a key patent application covering Anixa Biosciences, Inc.’s (NASDAQ:ANIX) ovarian cancer vaccine technology. The patent includes broad claims related to methods of eliciting an immune response targeting the Anti-Mullerian Hormone Receptor, Type II (AMHR2), a target for ovarian cancer prevention and treatment. Anixa’s ovarian cancer vaccine is being developed in collaboration with Cleveland Clinic an

Benzinga 16 days ago

ANIX
+13.03%
Anixa Biosciences CEO to Present at the 2025 CAGLA NeauxCancer Conference on March 28th

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its Chairman and Chief Executive Officer, Dr. Amit Kumar, will be presenting at the 2025 Cancer Advocacy Group of Louisiana ("CAGLA") NeauxCancer Conference taking place on March 27-29, 2025 at the The Roosevelt Hotel in New Orleans.

PR Newswire 23 days ago

ANIX
+13.03%
Is Gilead Sciences (GILD) Stock Outpacing Its Medical Peers This Year?

Here is how Gilead Sciences (GILD) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.

Zacks 30 days ago

GILD

ANIX
+13.03%
Anixa Biosciences 2025 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will host its 2025 Annual Meeting of Stockholders (the "Meeting") on Thursday, March 20, 2025 at 10:00 a.m. Pacific Time in a virtual format.

PR Newswire 30 days ago

ANIX
+13.03%
Anixa Biosciences Announces Chief Development Officer Dr. Pam Garzone to Speak at the Alliance for Cancer Gene Therapy Summit 2025 on March 19th

Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced Dr. Pam Garzone, Chief Development Officer of Anixa, will be attending the Alliance for Cancer Gene Therapy (ACGT) Summit 2025 and participating as a panelist on the Gynecologic and Breast Cancers panel. The Alliance for Cancer Gene Therapy Summit 2025 is being held on Wednesday and Thursday, March 19 - 20, 2025, at the Alexandria Center for Life

PR Newswire last month

ANIX
+13.03%
Spotlight On February 2025's Promising Penny Stocks

The U.S. stock market is experiencing mixed signals as investors process recent earnings reports and policy announcements, with the Dow Jones seeing gains while the S&P 500 and Nasdaq face slight declines. Amid these fluctuations, penny stocks present a unique opportunity for investors seeking growth at lower price points. Although often associated with smaller or newer companies, these stocks can offer significant potential when supported by strong financials and solid fundamentals.

Simply Wall St. last month

FDMT

ANIX
+13.03%
HUIZ
Anixa Biosciences and Moffitt Cancer Center Complete Dosing in Third Cohort in Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced has it has dosed its final patient in the third cohort of its ongoing Phase 1 clinical trial evaluating its novel chimeric antigen receptor-T cell (CAR-T) therapy for recurrent ovarian cancer. The study is being conducted through a research partnership with Moffitt Cancer Center ("Moffitt"). The fourth cohort is expected to commence after a

PR Newswire last month

ANIX
+13.03%
Anixa Biosciences' Breast Cancer Vaccine was Featured on Fox News' "America Reports"

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its breast cancer vaccine was featured on Fox News' "America Reports." The segment highlighted the potential of Anixa's vaccine to revolutionize breast cancer prevention by targeting the disease at its earliest stages.

PR Newswire last month

ANIX
+13.03%
Anixa Biosciences Featured in Breaking Cancer News Article on Novel CAR-T Therapy for Ovarian Cancer

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today is pleased to announce that its pioneering CAR-T therapy for ovarian cancer, developed in collaboration with Moffitt Cancer Center ("Moffitt"), was prominently featured in Breaking Cancer News in an article titled "Navigating Uncharted Territory: CAR-T for Ovarian Cancer."

PR Newswire last month

ANIX
+13.03%
Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?

Here is how Agenus (AGEN) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.

Zacks last month

AGEN

ANIX
+13.03%
Anixa Biosciences Announces Approval of Protocol Amendment for Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer today announced that it, along with its partner Moffitt Cancer Center ("Moffitt"), has received approval for an amendment to the protocol governing its ongoing clinical trial using CAR-T therapy for the treatment of ovarian cancer (NCT05316129).

PR Newswire last month

ANIX
+13.03%
Anixa Biosciences Chairman and CEO Discusses Pioneering CAR-T Cell Therapy and Breast Cancer Vaccine in Alpha Wolf Trading Interview

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its Chairman and CEO, Dr. Amit Kumar, was featured in an interview with Alpha Wolf Trading. In the discussion, Dr. Kumar provided insights into Anixa's groundbreaking CAR-T cell therapy for ovarian cancer and its breast cancer vaccine program, highlighting the Company's innovative approach to immunotherapy and cancer prevention.

PR Newswire last month

ANIX
+13.03%
Anixa Biosciences to Present at the 18th Annual European Life Sciences CEO Forum

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Mike Catelani, President and CFO of Anixa, will be participating in the 18th Annual European Life Sciences CEO Forum taking place February 26-27, 2025, at the Hilton Zurich Airport Hotel in Zurich, Switzerland.

PR Newswire last month

ANIX
+13.03%
Anixa Biosciences' Chairman & CEO Dr. Amit Kumar Featured on CW39's H-Town Live to Discuss the Future of Breast Cancer Prevention

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Amit Kumar, Chairman and CEO of Anixa, was featured on CW39's H-Town Live, where he discussed the Company's pioneering efforts in breast cancer prevention.

PR Newswire 2 months ago

ANIX
+13.03%

Performance Overview

Return	ANIX	S&P 500 (^GSPC)
YTD	+15.95%	-7.22%
1-Year	-17.23%	+4.74%
3-Year	+4.67%	+21.58%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Anixa Biosciences, Inc. (ANIX)

Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Covering Breast Cancer Vaccine Technology

EXCLUSIVE: Anixa Biosciences Receives Key US Patent Nod For Breast Cancer Vaccine Patent

Anixa Biosciences to Present at the Jones Las Vegas Healthcare and Technology Innovation Conference on April 9th

Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines

EXCLUSIVE: Anixa Biosciences Inks Letter of Intent with Austria-Based VERDI Solutions To Develop AI-Guided Personalized Cancer Vaccines

Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine

EXCLUSIVE: Anixa Biosciences Poised To Receive US Patent For Ovarian Cancer Vaccine

Anixa Biosciences CEO to Present at the 2025 CAGLA NeauxCancer Conference on March 28th

Is Gilead Sciences (GILD) Stock Outpacing Its Medical Peers This Year?

Anixa Biosciences 2025 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties

Anixa Biosciences Announces Chief Development Officer Dr. Pam Garzone to Speak at the Alliance for Cancer Gene Therapy Summit 2025 on March 19th

Spotlight On February 2025's Promising Penny Stocks

Anixa Biosciences and Moffitt Cancer Center Complete Dosing in Third Cohort in Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences' Breast Cancer Vaccine was Featured on Fox News' "America Reports"

Anixa Biosciences Featured in Breaking Cancer News Article on Novel CAR-T Therapy for Ovarian Cancer

Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?

Anixa Biosciences Announces Approval of Protocol Amendment for Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences Chairman and CEO Discusses Pioneering CAR-T Cell Therapy and Breast Cancer Vaccine in Alpha Wolf Trading Interview

Anixa Biosciences to Present at the 18th Annual European Life Sciences CEO Forum

Anixa Biosciences' Chairman & CEO Dr. Amit Kumar Featured on CW39's H-Town Live to Discuss the Future of Breast Cancer Prevention

Performance Overview